Earnings Report: Here’s what to expect from Recursion Pharmaceuticals (NASDAQ:RXRX)


Earnings results for Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. is estimated to report earnings on 08/11/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.23.

Recursion Pharmaceuticals last announced its earnings results on May 12th, 2021. The reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by $1.09. The business had revenue of $2.56 million for the quarter. Recursion Pharmaceuticals has generated $0.00 earnings per share over the last year. Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.10) to ($1.20) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 11th, 2021 based off prior year’s report dates.

Analyst Opinion on Recursion Pharmaceuticals (NASDAQ:RXRX)

5 Wall Street analysts have issued ratings and price targets for Recursion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $33.20, predicting that the stock has a possible upside of 18.15%. The high price target for RXRX is $36.00 and the low price target for RXRX is $31.00. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Recursion Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $33.20, Recursion Pharmaceuticals has a forecasted upside of 18.1% from its current price of $28.10. Recursion Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals does not currently pay a dividend. Recursion Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Recursion Pharmaceuticals (NASDAQ:RXRX)

In the past three months, Recursion Pharmaceuticals insiders have not sold or bought any company stock.

Earnings and Valuation of Recursion Pharmaceuticals (NASDAQ:RXRX

Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.10) to ($1.20) per share.

More latest stories: here